Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Description-11)

In this article, we will discuss Olaparib (Description-11). So, let’s get started.

Drug Interactions (2)

Based on the data from a drug-interaction trial (n=22), the AUC and Cmax of olaparib decreased by 87% and 71%, respectively, when olaparib was administered in combination with rifampicin, a strong CYP3A inducer. Simulations suggested that a moderate CYP3A inducer (efavirenz) may decrease the AUC and Cmax of olaparib by approximately 60% and 31%, respectively.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.